ER4 Stock Overview
A life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Emergent BioSolutions Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.93 |
| 52 Week High | US$13.78 |
| 52 Week Low | US$1.38 |
| Beta | 1.57 |
| 11 Month Change | 7.80% |
| 3 Month Change | 9.63% |
| 1 Year Change | 372.53% |
| 33 Year Change | -77.40% |
| 5 Year Change | -82.08% |
| Change since IPO | 8.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| ER4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 18.9% | -0.7% | 0.2% |
| 1Y | 372.5% | -17.2% | 8.5% |
Return vs Industry: ER4 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: ER4 exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| ER4 volatility | |
|---|---|
| ER4 Average Weekly Movement | 16.3% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: ER4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: ER4's weekly volatility has decreased from 23% to 16% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 1,600 | Joe Papa | www.emergentbiosolutions.com |
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector.
Emergent BioSolutions Inc. Fundamentals Summary
| ER4 fundamental statistics | |
|---|---|
| Market cap | €493.27m |
| Earnings (TTM) | -€200.51m |
| Revenue (TTM) | €1.08b |
0.5x
P/S Ratio-2.5x
P/E RatioIs ER4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ER4 income statement (TTM) | |
|---|---|
| Revenue | US$1.13b |
| Cost of Revenue | US$835.20m |
| Gross Profit | US$290.30m |
| Other Expenses | US$499.10m |
| Earnings | -US$208.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.85 |
| Gross Margin | 25.79% |
| Net Profit Margin | -18.55% |
| Debt/Equity Ratio | 130.3% |
How did ER4 perform over the long term?
See historical performance and comparison